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Abstract
Peritoneal carcinomatosis (PC) is the most impressive and frequent evidence of loco-
regional spread of epithelial ovarian cancer (EOC). For most of its natural history, PC
remains confined to the peritoneal district, thus representing a target for various
combinations of surgery and systemic or loco-regional chemotherapy. PC is observed
both in primary settings, i.e. in patients first treated for locally advanced EOC, and in
recurrent, previously treated, EOC patients at any FIGO stage. Since 2000s, the use of
hyperthermic intraperitoneal chemotherapy (HIPEC) combined with maximum
cytoreduction (peritonectomy) has gradually spread in the treatment of PC from
ovarian cancer, as well as for gastrointestinal carcinomatosis and primary tumours of
the peritoneum. Use of combined peritonectomy + HIPEC in the treatment of ovarian
carcinomatosis is the most discussed issue among those concerning peritoneal surface
malignancy (PSM). The main criticism concerns the use of HIPEC, since the need for
maximal cytoreduction is consolidated and does not raise any doubts. Communities
of surgeon and oncologic gynaecologists who believes in the role of HIPEC have
started controlled clinical trials aimed at clarifying the role of HIPEC associated to
peritonectomy, but these studies are difficult to conduct and time-consuming. At
present and pending the results of future prospective trials, the role and limits of
application of the procedure are drawn from experiences from three basic study
groups: collective reviews, multicentre studies, monocentric case studies produced
by high-volume HIPEC centers. A comprehensive literature review and an in-depth
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analysis of our personal experience, based on the largest monocentric case series (130
cases), have helped to provide an assessment on the role of peritonectomy + HIPEC
in about 2000 patients treated for initial and recurrent PC from ovarian cancer.
Comparison of the overall results drawn from these studies, indicates that peritonec‐
tomy + HIPEC is able to guarantee in these patients better overall survival (OS) and
higher progression-free survival (PFS) rates than those derived from traditional
treatments, with acceptable morbidity and mortality. Notwithstanding, some specific
aspects, including the role of chemoresistance and neoadjuvant and adjuvant
treatments, should be clarified by further experience and the results of on-going trials.
Keywords: Epithelial Ovarian Cancer, Peritoneal Carcinomatosis, Peritonectomy,
HIPEC
1. Introduction
Peritoneal metastasis is the most common type of diffusion and the most frequent cause of
death from EOC.
Intra-abdominal and pelvic parietal and visceral peritoneal metastases, often associated with
ascites, resectable hepatic metastasis, deep bowel wall infiltration up to mucosa, identify stage
III or IV ovarian cancer with diffuse PC [1,2]. Treatment of these conditions is traditionally
based on cytoreductive surgery (CRS) combined with systemic carbotaxol-based chemother‐
apy at first line. Despite high rates of chemosensitivity, relapses are detected in up to 50% of
cases in the first two years and in almost 100% in the first 5 years post-treatment. [3]
For most of its natural history, EOC is confined to the abdominal cavity, developing further
peritoneal tumour implants and producing pelvic and lumbar lymph node metastases without
extra-abdominal diffusion.
For this reason, new integrate therapeutic strategies have emphasized the role of local
aggressive treatments, represented by maximal cytoreductive surgery (peritonectomy)
combined with loco-regional HIPEC.
Peritonectomy (PRT) associated with HIPEC has been used since the second half of the 90’s in
the treatment of ovarian PC, as well as in other primary and metastatic peritoneal surface
malignancies.
PC is observed both in primary settings, i.e. in patients first treated for locally advanced EOC,
and as a recurrence in patients previously treated for ovarian cancer at any stage.
2. Initial and recurrent ovarian carcinomatosis
About 75% of ovarian cancers are diagnosed and treated in primary settings as FIGO Stage
IIIc/IV, meaning that they are confined to the abdominal and pelvic cavity and characterised
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by diffuse visceral and parietal PC [4]. PC is frequently associated with lymphnode metastases
and less commonly with haematogenous hepatic metastases.
Such a high percentage of PC at first presentation is mainly caused by the relevant delay in
diagnosing EOC at early stages, due to the lack of symptoms and to the low sensitivity and
specificity of diagnostic tools. Only 20% to 30% of EOC in developed countries are diagnosed
at FIGO Stage I and II and the diagnosis is usually accidental: either via sonography, compu‐
terised tomography (CT scanning) or during laparoscopic investigations [5,6].
The pathogenesis of late PC in patients already treated for EOC at any stage is more complex.
At FIGO stages I and II it may be related to a number of factors:
1. Limited and incorrect application of standard surgical procedures;
2. Inherent limitations to the procedures established by international guidelines;
3. Chemoresistance.
Point 1 of the above is sometimes dictated by special clinical situations, which require
conservative treatment. Young patients with small ovarian tumours can be treated with simple
unilateral oophorectomy, in order to preserve their reproduction function. The results of this
strategy are not uniform and tend to show an unjustifiable risk of surgical relapse. Rupture of
the ovarian tumour during open surgery, or more often during laparoscopic surgery, is one
of the most frequent cause of peritoneal recurrence [7].
Omission of appendectomy or total omentectomy is also not a rare cause of peritoneal
recurrence or persistence of the disease (Fig. 1).
As to point 2, despite international guidelines advice for infra-colic limited resection of the
greater omentum and for not total omentectomy, the presence of histologically-proven tumour
implants in the latter tissue is associated to elevated rates of peritoneal and omental recurrence.
Figure 1. Residual greater omentum involved in recurrent peritoneal carcinomatosis.
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On the other hand, the anatomical structure of the omentum is unitary and limited resection
is, therefore, not plausible. It should be reminded that the omentum often harbours EOC
deposits by virtue of its peculiar anatomy and function. It contains milky spots, which are
responsible for the concentration and reabsorption of intraperitoneal fluid, including malig‐
nant ascites. It is through the milky spots that the tumour cells take root into the omentum.
This phenomenon facilitates the formation of carcinomatous nodules of various sizes, in some
cases involving the complete replacement of the omental tissue with tumour tissue ("omental
cake").
Omission of lymphadenectomy in early stage EOC is frequent and correlates significantly with
subsequent loco-regional lymph-node metastases and PC (over 50% in our series of recurrent
EOC patients).
Finally, chemoresistance to first-line adjuvant treatments with carbotaxol is detectable in 20%
of cases and is a further cause of relapse after treatment for stage I and II EOC [8].
Peritoneal recurrences after treatments for FIGO stages III or IV intraperitoneal EOC, can be
mainly attributed to the lack of aggressiveness of the standard treatments. The current
standard therapy, i.e. CRS combined with systemic chemotherapy, shows limited efficacy in
high stage EOC, and is followed in most cases by abdomino-pelvic loco-regional recurrence.
Most often relapses occur as PC, associated with ascites in 60% of cases.
Further attempts to treat ovarian cancer at stage III — aimed at curbing the incidence of
peritoneal recurrence — involve the use of intra-peritoneal normothermic chemotherapy (IP
CHT).
Several randomized trials have demonstrated the effectiveness of this method, especially after
optimal CRS; nevertheless it is still rarely used mainly due to catheter-related complications
which significantly reduce its applicability. [9,10]
In conclusion, PC is the most frequent and characteristic manifestation of EOC, whether
identified early at first assessment or later as persistent or recurrent disease following standard
treatments. These include surgical debulking and systemic chemotherapy, are characterised
by high recurrence rates and cannot guarantee long-term survival and improvement in the
quality of life.
3. Epidemiology
EOC affects over 200.000 women and causes 125.000 deaths annually worldwide, with a
deaths/new cases ratio of 62,5 % [11]. These data demonstrate that standard treatments are not
able to deal effectively with this disease, and success rates are distant from other common types
of cancer, such as colorectal cancer, for which the deaths/new cases ratio was 45.9% over the
same period. The low impact of standard treatments is also corroborated by the analysis of the
causes of death for EOC patients. Our National Institute of Statistics (ISTAT) data referred to
2013-2014 showed that 80% of deaths in EOC patients is exclusively due to peritoneal recur‐
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rence, 10% to peritoneal recurrence associated with extra-peritoneal metastasis, and only 10%
exclusively to extra-peritoneal metastases. Therefore, alternative therapeutic strategies are
needed, also considering that distant metastases are a late occurrence in EOC patients, mainly
due to the little effectiveness of standard treatments.
4. Macroscopy and microscopy
Traditionally the origin of carcinomas of the ovary is identified in the Ovarian Surface
Epithelium (OSE). Growing evidence indicates that the majority of EOC have an extraovarian
source. [12]
The new paradigm that increasingly fits with the extraovarian origin of EOC establishes
common characteristics for ovarian, tubal and primitive peritoneal tumours that unite these
malignancies in a common family, divided into two broad groups: type I and type II ovarian
cancers.
Molecular profiling contributes to better distinguish the two types of ovarian cancer (high
grade vs. low grade) as well as identifying various subtypes, i.e., serous, mucinous, endome‐
trioid and clear cell cancer.
The application of these new classifications will be invaluable in identifying “ovarian”
tumours with different prognosis and targets for specific therapeutic strategies. [10]
Major studies on ovarian PC include ovarian, tubal and primitive peritoneal carcinomas
grouped together due to their histological and pathological similarities and the treatment
options which are identical for all three forms.
Macroscopically the ovarian carcinomatosis is similar to other forms of PSM. It can be present
as nodules varying in size from less than 1 mm to various centimetres, isolated or conglom‐
erated in the form of solid or cystic masses or plaques of varying sizes and thicknesses.
The serous or mucinous content of carcinomatous implants and their degree of invasiveness
of the peritoneum and of the underlying structures is extremely variable.
Previous treatments with chemotherapy can influence the appearance of ovarian carcinoma‐
tosis. After neoadjuvant or adjuvant chemotherapies, the peritoneum can show evident signs
of carcinomatosis regression on its surface, ranging from significant reduction to complete
disappearance; in each case the signs of previous disease are still evident.
In particular, the increase in thickness of the parietal and visceral peritoneal membrane, its
opacification, and the presence of blurs and reddish spots indicate the location and extent of
previous carcinomatosis.
Histological and immunohistochemical studies of biopsies of these tissues often show the
presence of microscopic foci of disease in the context of thick, fibrotic areas.
These macroscopic and microscopic features are potential justifications for relapse after
neoadjuvant or adjuvant chemotherapy in patients subjected to an apparently negative
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second-look. Indeed, fibrosis encapsulating foci of neoplastic cells may preserve them from
effects of further systemic or locoregional therapies.
Furthermore, total chemical cytoreduction runs the risk of both surgical and chemotherapic
undertreatment, especially if obtained after effective neoadjuvant treatments.
PC may involve any anatomic site and bowel segment or parenchyma in high percentages
(parietal and visceral peritoneum 90%; omentum 60%; diaphragm 40%; liver and spleen
capsule 15%). Lymphatic and haematogenous metastases in the liver may also be detected
contemporaneously (respectively 50-60% and 5%). Ascites is present in about 60%.
5. Diagnosis and staging of peritoneal carcinomatosis
The ovarian carcinomatosis is paucisymptomatic until it assumes a considerable size or is
associated with ascites or occlusion. Therefore diagnosis is often delayed and more than 70%
of ovarian cancer patients are diagnosed at FIGO stages IIIC/IV.
Clinical examination with vaginal and rectal exploration plays a critical role in assessing the
pelvic spread of the disease.
Diagnosis is based on a set of efficient morphological investigations (CT, MRI, PET). CA 125,
in association or not to CA 19.9, and currently to HE-4, are the most sensitive tumour markers
for specific diagnosis of ovarian cancer. Laparoscopy plays an important role in doubtful cases,
allowing the direct visualization and biopsy of suspected lesions.
Figure 2. Microfocus of neoplastic cells inside fibrous desmoplastic tissue- CA-125 immunohistochemistry.
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The intraoperative staging of PC from ovarian cancer, as in other forms of PSM, relies mainly
on PCI classification proposed by Sugarbaker [13], although other classifications have been
proposed.
The correct staging of PC is important to assess resectability, prognosis and risk of complica‐
tions. For this reason, much effort is made to adopt the PCI classification also prior to surgery
by applying it to data from morphological imaging (CT, MR, PET) or laparoscopy investiga‐
tions.
Being able to determine reliably in the preoperative phase the peritoneal spread of the disease
and the involvement of sensitive anatomical areas, PCI could avoid unnecessary surgical
approaches and improve the overall strategy as well as identify cases to be submitted to
neoadjuvant chemotherapy (NACT).
However results are still unsatisfactory both due the complexity of PCI classification and the
difficulty in its preoperative application; recently a new and simpler method to stage peritoneal
carcinomatosis via laparoscopy has been proposed [14].
If the above described set of diagnostic procedures increases the percentage of successful
diagnosis of PC, including the identification of the primary tumour and the eventual presence
of extra-peritoneal disease, the reliability of the current standard diagnostic tools used in
staging intraperitoneal spread must be considered as unsatisfactory. Many authors emphasize
the role of laparoscopy in staging intraperitoneal spread of carcinomatosis, but the obvious
limits of feasibility in pervasive forms of recurrence restrict the use and significance of this
method [14-17]. Moreover risk of contamination of port site access by tumor cells at laparo‐
scopy should be considered [18-20].
6. Evaluation of residual disease after cytoreductive surgery
Evaluation of tumor residues after cytoreductive surgery is of relevant importance because of
residual disease volume is the major prognostic factor in the treatment of EOC.[21-30]
The degree of cytoreduction can be assessed with various classification systems, the most used
of them is the Sugarbaker scoring classification [Completeness of Cytoreduction score (CC)]
[31]. This system provides four values from 0 to 3, where 0 indicates complete cytoreduction
of peritoneal carcinomatosis with total absence of macroscopic residual disease at the end of
the surgical phase. The maximum therapeutic efficacy of the integrated procedure is carried
out in cases where an ”optimal” cytoreduction (CC0 - CC1) is achieved.
7. Peritonectomy and HlPEC
The limits of success of standard treatments of PC from ovarian cancer have led to test new
therapeutic possibilities, borrowing from the experiences made in other forms of peritoneal
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carcinomatosis a therapeutic strategy based on the association of maximal cytoreduction
(Peritonectomy) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Peritonectomy is aimed to complete removal of macroscopic disease; HIPEC is aimed to treat
microscopic or millimetric tumor residues after surgical cytoreductive phase.
7.1. Rationale
The association between PRT and HIPEC is based on a complex rationale that takes into
account the mechanism of intraperitoneal spread of free cancer cells, Gompertzian tumor
growth kinetics, Goldie&Coldman mathematical model about drug resistance, pharmacoki‐
netic and pharmacodynamic events related to intraperitoneal chemotherapy associated with
hyperthermia. [32]
Maximal cytoreduction reducing drastically tumor volume, induces the remaining cells to
enter the fast proliferating phase of the cell cycle becoming more responsive to chemotherapic
drugs. Moreover microscopic or millimetric residual tumor volumes include a minor rate of
chemoresistant clones and can be totally permeated by drugs delivered by intraperitoneal
chemotherapy [33-36].
The association of HIPEC is based on a series of advantages related by a part to the fact that
the chemotherapy is carried out at the end of the surgical stage directly into abdominal cavity
and by the other part to the fact that drugs used are brought to a constant temperature of 42-43°
for the entire treatment period of infusion (usually 60 minutes).
The benefits of loco-regional chemotherapy consist of:
• direct exposure of whole anatomical region to chemotherapy being absent adhesions
• possibility of using high concentrations of chemotherapics
• possibility of allowing a prolonged exposure time
• low systemic toxicity
The combination of hyperthermia provides additional benefits:
• hyperthermia damages cancer cells
• increases the effectiveness of some chemotherapics (CDDP, MMC, DOX, gemcitabine)
• does not involve increased toxicity
• promotes tissue penetration of chemotherapeutic drugs
In particular, hyperthermia favours drug penetration into the tissues to a depth of 5 mm, a
value significantly greater than what occurs in isothermal conditions (2 mm). Therefore the
more the peritonectomy is effective achieving “optimal” cytoreduction (CC0 - CC1), i.e. up to
allow the total removal of the disease or leaving residues of minimum size (up to 2.5mm), the
more associated chemo-hyperthermia will be able to successfully attack microscopic or
minimum size tumor residues.
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8. Peritonectomy
The term of peritonectomy identifies precisely the meaning of the surgical procedure: removal
of parietal and visceral peritoneum affected by the neoplastic pathology.
Peritonectomy procedures comprise:
• exeresis of parietal peritoneum
• exeresis of visceral peritoneum by visceral and parenchymal resection
• excision/in situ destruction of single implants
• resection of abdominal wall, muscle implants and laparoscopic trocar sites
• lymphadenectomy
At parietal level the procedure entails complete or partial removal of the peritoneum lining
the abdominal wall, the diaphragms and the pelvis according to disease extension. General
consensus is in removing parietal peritoneum limited to involved areas, sparing a unaffected
zones.
If healthy areas are limited, large parietal peritonectomies should be performed up to complete
parietal peritonectomy.
In principle, the resection of the parietal and pelvic peritoneum below the transverse umbilical
line should be performed in all cases of peritoneal carcinomatosis from ovarian cancer.
Parietal peritonectomy includes greater and lesser omentectomy, resection of round and
falciform ligaments, stripping of omental bursa peritoneum.
When PC spreads deeply beyond peritoneal membrane trough abdominal wall, full or partial
thickness parietal resection is performed.
Laparoscopic trocar sites are removed by full thickness cylindrical parietal resection when
involved by carcinomatosis or when suspected to be contaminated by tumor cells. Umbilicus,
regardless its previous use as trocar sites, should be removed on principle in recurrent cases
being a frequent site of metastasis.
Visceral peritoneum cannot be separated from underlying visceral tissue and removed
separately as with the peritoneum lying the abdominal walls and diaphragms. Therefore
visceral peritonectomy involves exeresis of endoperitoneal viscera or organs deeply infiltrated
by PC. Rarely and only in special anatomical situations is possible the removal of visceral
peritoneum only as when PC does not deeply infiltrate the visceral wall or when it concerned
the Glisson’s capsule.
Bowel resection is the most frequent peritonectomy procedure in treating peritoneal carcino‐
matosis from ovarian cancer.
Contemporaneous involvement of multiple viscera induces to multivisceral resections for
what en bloc resection should be preferred (Fig 3-4).
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Figure 3. Pelvic peritonectomy: the moment of rectal resection as final step to remove en-bloc the surgical specimen.
Figure 4. Pelvic peritonectomy: en bloc resection of uterus, adnexa, rectosigmoid colon, pelvic and iliac fossae perito‐
neum, right colon and greater omentum.
Small and large bowel resections are the most frequent surgical procedures because of deep
parietal involvement by tumor implants. Thickness of the gastric wall is such as to allow
prevailingly a conservative cleaning of the tumor implants without the need to perform major
gastric resections.
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Among large bowel resections, which may include all types of colon resection, left colorectal
exeresis is the most frequent. Widespread pelvic involvement by primary tumor and peritoneal
metastases with infiltration of the pouch and colorectal wall, provides colorectal resection.
Such exeresis should include mesorectal resection and section of mesenteric vessel at their
origin to achieve the same radicality requested for primary colorectal cancer treatment. Same
radicality criteria should be followed resecting other large bowel sectors. This policy allows
to remove both a large amount of mesocolon, frequently infiltrated by implants, and loco-
regional lymph nodes which are metastasized in over 50% of cases. [37]
Lymphadenectomy plays a relevant role in strategy of peritonectomy for ovarian carcinoma‐
tosis and its prognostic role is highly significant: the only performing the procedure involves
a significant increase in survival regardless metastastic involvement of lymph nodes[38-40].
The incidence of loco-regional lymph node metastasis is high exceeding 50% of cases and
should induce a policy of radicalization of surgery in lymph nodes as well as in peritoneum.
Iliac-obturator and lumbar lymphadenectomy must be performed routinely in primary forms.
In secondary forms lymphadenectomy should be performed if it was not done in previous
surgery, or if it has been made necessary by evident nodal relapse in the seats already treated.
Additional forms of lymphadenectomy, at the level of hepatic pedicle, splenic hilum, mesen‐
tery or lesser omentum should be performed in the presence of lymphadenopathy macro‐
scopically evident.
9. Removal / “in situ” destruction of implants
The treatment of peritoneal implants does not absolutely require the exeresis of wide portions
of peritoneum or the mandatory sacrifice of wide tracts of gut or other structures involved in
the disease. In relation to quality, quantity, and macroscopic and microscopic (histology)
characteristics of carcinomatous implants, the exeresis should respond to general criteria of
saving structures and avoiding useless tissue and visceral sacrifices, when local removal or in
situ destruction with an appropriate technology allow a radical result.
A conservative approach is achievable when implants are superficial, few infiltrating the
underlying structures, and when are prevailingly mucinous. In these conditions, it is possible
to spare wide visceral resection especially when small or large intestine are involved. Local
excision or local destruction can be assured effectively with curved scissors, electric scalpels
with various tips, radiofrequency (Tissue Link), argon beam laser.
In patients undergone neoadjuvant treatments an additional contribution to HIPEC efficacy
is given by argon or electric scalpels use over peritoneal areas where an apparent response to
chemotherapy was achieved.
These areas are identified by the presence of specific morphological changes, including
opacification, thickening, fibrosis of serous peritoneal membrane and presence of red spots.
Peritonectomy Procedures and HIPEC for Peritoneal Metastasis from Ovarian Cancer
http://dx.doi.org/10.5772/60844
101
Extensive treatment on such areas with argon or ball tip electro-surgery permits diffuse local
damage and partial destruction of fibrosis.
The loss of structural continuity will permit a deeper tissue penetration of chemotherapics and
a better contact with eventual encapsulated microscopic residuals in post-chemotherapy
fibrosis.
10. HIPEC
HIPEC is performed at the end of surgical phase by using a 2.5-4.5 litres solution of chemo‐
therapy drugs. Chemotherapy drugs, HIPEC techniques and duration are synthesized in Table
1. Drug solution is infused in peritoneal cavity by catheters appropriately positioned (fig.5).
Infusion is performed under a constant temperature of 41-43°.
Figure 5. Intra-abdominal catheter position for HIPEC
Open and closed techniques are used for HIPEC but no proven advantage is related to a specific
method.
Procedure duration varies from 60 to 90 minutes and CDDP is drug prevailingly administered.
No specific prospective studies have been conducted to verify differences in outcome by
specific technique or to test the role of different chemotherapy regimens or drugs.
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STUDY HYPER-O[44]
DERACO
[45]
BAKRIN
[42]
DI GIORGIO
[48]
DE BREE
[43]
HIPEC DRUG
CDDP 37.2% - 41% 100% nr
Oxaliplatin - - 21.3% - nr
MMC 38.7% - 2.1% - nr
CarboTaxol 14.6% - - - nr
Doxorubicin - - 0.2% - nr
Combination (≥2) 9.5% 100% 35.4% - nr
HIPEC DURATION
60 min - - - 100% nr
60-90 min 45.4% 100% - - nr
90-120 min 54.6% - - - nr
HIPEC TECHNIQUES
Open 12.1% - 68.4% - nr
Closed 87.9% 100% 31.6% 100% nr
Table 1. HIPEC drugs, duration and techniques. nr: not reported.
11. Inclusion and exclusion criteria
General criteria provide to include in the therapeutic program patients without extrabdominal
disease with optimal ASA and Performance Status scores and with surgically cytoreducible
peritoneal carcinomatosis. Isolated and easy resectable liver metastases are not contraindica‐
tion to procedure performing when complete cytoreduction can be achieved. High level of PCI
is not an absolute contraindication if surgery can obtain optimal cytoreduction although some
authors identify levels beyond which the procedure is not advisable[14, 41-42].
Exclusion criteria include:
• great vessels involvement
• massive involvement of small bowel for over 50% of the length or of its mesenteric root
• infiltration of duodenum, pancreas or first jejunal loop
• infiltration of cardia or diaphragmatic pillars
• metastastic lymphadenopathy above the renal vessels
• extra-abdominal metastases
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Age and comorbidity are relative exclusion criteria, being ASA and Performance Status scores
the most reliable criteria to be considered even in patient in their eighties or suffering of other
concomitant diseases.
12. Settings
Peritonectomy combined with HIPEC can be used as primary cytoreduction or as secondary.
Primary cytoreduction can be performed as frontline or after neoadjuvant chemotherapy as
interval debulking surgery. Secondary cytoreduction is performed in patients with recurrent
or persistent disease after previous cytoreductive surgery combined or not with various forms
of chemotherapy. Tertiary and quaternary cytoreduction combined or not with HIPEC can be
performed in patient with repeated intraperitoneal relapses. PRT + HIPEC can be used as
consolidation in primary setting during a second look in patients optimally treated with
neoadjuvant chemotherapy or in secondary setting during a second look after any combination
of surgery and locoregional or systemic chemotherapy.
13. Results
Over the last 15 years the use of peritonectomy combined with HIPEC has progressively
widespread as treatment of peritoneal carcinomatosis from ovarian cancer. Phase III trials
about the efficacy of such integrated procedure compared to traditional treatments based on
CRS and systemic or normothermic intraperitoneal chemotherapy (IP CHT) are not available.
Therefore the role and limits of application of PRT+HIPEC are inferable by results of phase I
and mainly phase II studies. At present an overall analysis of the literature allows us to manage
data from over 1900 treated cases (Table 2). Collective reviews, multicentric and monocentric
case studies are the most available bases to verify the role of PRT combined with HIPEC in
treating peritoneal carcinomatosis from ovarian cancer.
Among available collective reviews, the study of de Bree and Helm of 2012 is the more recent
and complete. This study is based on 1102 cases collected from 22 monocentric studies and
includes the three major previous reviews conducted by Bjelic, Chua and de Bree himself [43,
46-47]. The three multicenter study published between 2010 and 2013 are reported; their study
designs were retrospective or prospective phase II. As for monocentric studies, results of a
clinical phase II prospective study about the use of PRT and HIPEC in treating peritoneal
ovarian carcinomatosis performed by the authors of this chapter is reported. This study is
based on 130 cases treated between November 2000 and December 2013 in the same center
and by the same staff [48]. This is the largest monocentric case study compared to all other
reports included in the collective review of de Bree, the major of which consists of 81 cases.[49]
The multicenter study of Deraco includes exclusively cases undergoing primary CRS as front
line, while that of Bakrin comprises prevailingly cases treated for recurrence (83,8%). In the
other studies the rates of primary and secondary CRS were almost similar.
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Author
Year
De Bree 2012
[43]
Helm
(HYPER-O) 2010
[44]
Deraco 2011
[45]
Bakrin
2013
[42]
Di Giorgio
2014
[48]
Type of study CollectiveReviews Multicenter Multicenter Multicenter Monocentric
Study Design Collection ofphase II studies Retrospective
Prospective
phase II Retrospective Prospective phase II
Frontline 18.4% 18.5% 100% 2.1% 17.7%
Interval debulking 5.6% 13.6% - 4.2% 29.2%
Consolidation 8.9% 8,6% - 9.9% 5.4%
Recurrence 67.1% 5.3% - 83.8% 47.7%
No. Cases 1102 141 26 566 130
Table 2. PRT + HIPEC for peritoneal carcinomatosis from EOC: literature review.
PCI mean ranged from 10.6 to 16.3 and in all series the rate of patients classified as FIGO stage
III and IV exceeded 90 %(Tab.3).
Author
Year
De Bree 2012
[43]
Helm
(HYPER-O) 2010
[44]
Deraco 2011
[45]
Bakrin
2013
[42]
Di Giorgio
2014
[48]
No. Cases 1102 141 26 566 130
PCI mean nr nr 15.5(5-26) 10.6(0-31) 16.3(0-39)
CC score 0
=1
>1
nr
58.3%
15.1%
26.6%
57.7%
42.3%
74.9%
17.9%
7.2%
66.7%
20%
13.3%
Platinum response
resistant
sensitive
undetermined
nr
34%
53.9%
12.1%
nr
52.1%
47%
0.9%
36.8%
53.8%
9.4%
Adjuvant Chemotherapy
yes
no
nr 93.6%6.4% 100%
28.3%
71.7%
71.5%
28.5%
Table 3. Patients characteristics. nr: not reported.
Peritonectomy was able to achieve optimal cytoreduction in most cases and the rates of
complete cytoreduction ranged from 57,7 to 74,9, being the better scores related to lower level
of PCI mean.
Platinum based drugs were the most used during HIPEC, alone or in combination with other
chemotherapics. Adjuvant systemic chemotherapy was administered in post HIPEC phase in
the vast majority of cases.
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14. Survival
Results related to survival are synthesized in Tab 4 - 6.
Author - Year Helm (HYPER-O) 2010[44]
Bakrin 2013
[42]
Survival 5 yr OS % Median OSmonths 5 yr PFS %
Median PFS
months 5 yr OS % Median OS months
Frontline 33.3
25.4
41.7
30.3
19.7
13
24.8
13.7
33.7
17
52.7
35.4Interval debulking 50.2 68.6 9.6 16.8 16 36.5
Consolidation 42.4 53.7 24.2 29.6 12.5 33.4
Recurrence 18 23.5 9.6 13.7 37 45.7
CC0
Primary 26.7 37 - - 23.6 41.5
CC0 Recurrence - - 40.2 51.5
Author – year Deraco 2011[45]
Survival 5 yr OS%
Median OS
months
5 yr PFS
%
Median PFS
months
Frontline 60.7 not reached 15.2 30
Table 4. PRT + HIPEC for peritoneal carcinomatosis from EOC: survival in multicentre studies.
Author - Year De Bree 2012[43]
Survival 5 yr OS%
Median OS
Months
5 yr PFS
%
Median PFS
months
Frontline 47
58.5
33
66.5
17,5
36.5
25
35Interval debulking 54 69 10 17
Consolidation 84 64 63 35
Recurrence 33 42.5 11.5 20.5
CC 0
Primary -
66
(only frontline) - -
CC 0
Recurrence - - - -
Table 5. PRT + HIPEC for peritoneal carcinomatosis from EOC: survival in collective reviews
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Author – year Di Giorgio 2014 [48]
Survival 5 yr OS%
Median OS
Months
5 yr PFS
%
Median PFS
Months
Frontline 57.6
50.7
63.1
61.1
38
43.1
38.5
38.5Interval debulking 41.2 37.4 39.7 21
Consolidation - -
Recurrence 45 40 29.5 17.7
CC0
(primary) 59.6 50.5 53.7 56.8
CC0 (recurrence) 61.3 66 42.2 52
Table 6. PRT + HIPEC for peritoneal carcinomatosis from EOC: survival in author’s monocentric study.
In all studies except one, patients treated in primary setting tend to survive more than
recurrent; only Bakrin reported better 5- year overall survival in secondary setting (Fig 6).
In an half of reports, 5- year overall survival rate was about 50 % after primary CRS and about
40% after secondary CRS. Overall PF survival ranged across the reported studies between 13
to 43.1% at 5 years.
% 
Figure 6. yr Overall and Progression Free survival after primary and secondary CRS +HIPEC
The values of median survival, both overall and progression free, reflected the general trend
of 5-year survival: except for Bakrin’s study, patients treated in primary setting survived more
than patients treated for recurrence (Fig. 7).
Among patients treated in primary setting, patients undergoing PRT and HIPEC as front line
tended to survive more than those neoadjuvated. Data from HYPER-O report are not available
by admission of their Authors because of the small number of events
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Results about long term prognosis in patients with PRT and HIPEC administered as consoli‐
dation during a second look are not useful for an advisable evaluation because of scarce
number of treated cases in all analyzed studies.
 
 
% 
Figure 8. yr Overall and Progression Free survival in primary setting
14.1. Prognostic factors
A lot of potential prognostic factors have been analyzed by uni- and multivariate analyses and
completeness of surgical cytoreduction (CC) resulted as the most significant prognostic factor
in all series. Among the others, PCI was significantly related to survival in 3 of the 4 studies
where has been analyzed.
Platinum response, blood loss, level of bowel wall infiltration by tumor implants, lymph node
metastases, use of carboplatin and duration of perfusion, correlated significantly with survival
at least once across the study by uni- or multivariate analyses.
14.2. The role of completeness of cytoreduction and PCI
Since 1970s results of treatment of locally advanced epithelial ovarian cancer emphasized the
role of surgical debulking aimed not only at palliation of clinical status borned from intraper‐
 
Figure 7. Median Overall and Progression Free survival after primary and secondary CRS+HIPEC
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itoneal disease spread but also to improve long term survival. [50]. The concept of optimal
cytoreduction correlated to the dimension of tumor residuals among gynecologic oncologist
has progressively induced to reduce from 2 cm to 0.5 cm the maximum acceptable limit. Among
surgical oncologist according to Sugarbaker classification such limit is up to 2.5 mm. The role
of cytoreduction level in primary resection for locally advanced EOC is well highlighted by
the most relevant retrospective and prospective studies reported in literature [51-53].
A meta-analysis of 6.855 cases confirmed these data [54]. The most significant gap was
observed between patient without any residue and those with residues of any size. Even in
patients undergoing cytoreductive surgery for recurrent disease a lot of retrospective studies
[21-30] and a meta-analysis including 2.019 patients [55] confirmed the prognostic role of
maximal cytoreduction. Maximal or optimal cytoreductive surgery are correlated to evident
advantages improving patients quality of live, decreasing drug resistance clones entity and
improving chemotherapy efficacy. Complete removal of peritoneal disease proves to be the
Author
Year
De Bree and
Helm
2012
[43]
Helm
(HYPER-O)
2010
[44]
Deraco
2011
[45]
Bakrin
2013
[42]
Di Giorgio
2014
[48]
Prognostic Factors Primary Recurrence Primary Recurrence
CC score nr 0.025 nr 0.005 0.0001 0.003 0.009
PCI nr nr nr 0.0012 0.0001 0.008 0.007
PS nr nr nr ns 0.0224 ns 0.006
Setting nr ns nr nr nr ns ns
Platinum response nr 0.048 nr nr ns 0.0005 ns
Blood loss nr 0.005 nr nr nr ns 0.0004
Ca125 nr nr nr 0.0241 0.2131 ns ns
Lymph node
metastases nr nr nr nr nr 0.002 ns
Age nr nr nr 0.0574 0.0314 ns ns
Bowel wall
infiltration nr nr nr nr nr 0.0002 0.01
HIPEC drugs
number nr nr nr 0.9689 0.0176 ns ns
HIPEC drug type nr 0.011 nr 0.2653 0.7098 ns Ns
Duration of
perfusion nr 0.047 nr nr nr ns ns
Table 7. PRT + HIPEC for peritoneal carcinomatosis from EOC: prognostic factors by uni or multivariate analyses. [nr:
not reported; ns: not significant]
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most relevant prognostic factor in all setting even in all analyzed studies on HIPEC here
reported (Tab 6).
Some authors argued about the role of PCI in selecting patients to be treated with peritonec‐
tomy and HIPEC, identifying level of diffusion of peritoneal disease by scores beyond which
such combined procedures should be avoided. In particular Bakrin identified in a value of PCI
equal to 10 that limit in relation to related poor prognosis, while other authors [14] identify
specific laparoscopic scoring of diffusion of peritoneal carcinomatosis to predict the achieve‐
ment of an optimal cytoreduction.
Results of our monocentric study show that in PC from ovarian cancer high degrees of PCI are
not an absolute limit to the execution of the procedure, if it is possible to obtain an optimal
cytoreduction. We believe that high degree of PCI does not constitute an absolute contraindi‐
cation to cytoreduction, as some claim [41, 56] and that rather one should take greater account
of technical feasibility, quality of carcinomatosis of the individual case and possibility of
obtaining an optimal cytoreduction. In our series, which had a PCI mean of 16.3, patients with
PCI> 16 have nevertheless demonstrated a 5-year overall survival of 24.3%, with no difference
between primary and secondary CRS, and a 5 year survival of 50.2 % (median 61.1 months)
when in these patients with high PCI a complete cytoreduction (CC0) was obtained.
14.3. The role of NACT
Diffuse Peritoneal Carcinomatosis in primary setting is ideal target for neoadjuvant chemo‐
therapy with carboplatin and taxol, due to high rate or responsiveness when administered as
first line treatment (> 80%).
Nevertheless advantages of such strategy are not clear and results are conflicting, both in
patients treated with and without HIPEC.
In patients undergoing NACT and successively treated with standard cytoreductive surgery
and systemic chemotherapy, preoperative chemotherapy failed to improve survival. In
EORTC 55971 phase III trial, NACT increased the rate of optimal Cytoreduction and decreased
post-operative morbidity compared to front line CRS, but did not influence Overall or PF
survival [57-58].
Similar results have been observed also in the studies related to the role of NACT in patients
treated with PRT + HIPEC[59-60].
A better comprehension of significance of this strategy may drawn from analysis of chemo‐
sensitivity during NACT. In our monocentric series more than 50% of patients treated in
primary setting undergo carbo-taxol-based NACT. 26,3 % didn’t respond to this regimen and
demonstrated a significant worse prognosis (29,4% 5-yr OS) compared to cases treated front
line or NACT responders (56,4% 5-yr OS).
Some studies envisage for NACT disadvantages related to increased risk of platinum resist‐
ance during post-CRS adjuvant chemotherapy [61] or post-NACT histological changes
occurring in tumor tissue that correlate with a poor prognosis [62]. These data are reflected in
our cases: neoadjuvated patients showed a higher percentage of chemoresistance during post-
HIPEC treatment with platinum derivatives (41.7%) than those not neoadjuvated (31.8%) and
survived less.
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In the near future the results of ongoing trials will better highlight the optimal strategy in using
NACT. Based on results of studies now available, NACT regimen should be personalized and
administered to patients with bulky intraperitoneal disease at risk of incomplete CRS, or to
patients with small metastatic pleural effusion or with small isolated liver metastasis easily
resectable during CRS.
14.4. The role of platinum chemoresistance
The role of platinum chemoresistance has been analyzed in three studies and in two of them
chemoresistance resulted as a negative prognostic factor [44, 48 - Tab 6]
In two studies platinum chemoresistance was analyzed in pre-HIPEC phase in patients treated
for recurrence while in our monocentric study we have evaluated the chemoresistance by
referring to the recurrence/progression within six months after the end of post-HIPEC adjuvant
treatment with platinum-based drugs, both in primary and in recurrent forms.
In the two multicenter studies where chemoresistance was analyzed in pre- HIPEC phase, it
didn't influence survival in Bakrin’s report while resulted marginally significant in HYPER-O
registry.
In our series,Platinum chemoresistance so assessed was related to a worse prognosis only after
primary CRS plus HIPEC, with both univariate and multivariate analyses (Table 6). The
negative correlation between platinum chemoresistance and prognosis in primary forms can
be partly explained by the possibility that NACT determines chemoresistance against the
platinum used in systemic form after CRS as described above [62].
In our series, post-HIPEC chemoresistance did not influence significantly survival of recurrent
patients, whose rates of platinum chemoresistance and chemosensitivity were similar (47.2%
vs 52.8%).
In patients treated for recurrence, PRT combined with HIPEC may induce, especially for cases
CC0, a reset of previous oncologic situation and that the chemosensitivity assessment to
platinum based drugs chemotherapy post-HIPEC more faithfully represents the new relation‐
ship between patient and such chemotherapics. Moreover, the possibility that the CRS
associated with HIPEC may lead to a retrieval of chemoresistance to platinum is theorized by
some authors [54].
14.5. The role of bowel wall infiltration
Among the analyzed studies carcinomatous infiltration of intestinal wall has been analyzed
only in our monocentric study. Progressive infiltration of bowel wall influenced negatively
long term survival. The impact of the degree of parietal layers infiltration like the T role in
TNM staging of gastro-intestinal tumor but in an inverse sense has been analyzed in previous
report by us and other authors in relation to only colorectal resection [63-65]
Recently the evaluation of bowel wall infiltration up to the mucosa has been included in new
2014 FIGO stage for ovarian cancer identifying mucosal infiltration as FIGO stage IVb [1,2].
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14.6. The role of lymphadenectomy
The role of lymphadenectomy and significance of lymph node metastatic involved in locally
advanced EOC is controversial. Lymphadenectomy is supported from some authors on the
basis of its positive influence on survival [66-67], while other authors are skeptical [68]. The
high rate of loco-regional lymph node metastases justify systematic lymphadenectomy in
primary setting on principle and in secondary setting when not performed during primary
cytoreduction.
The significance of lymph node metastasis was analyzed only in our monocentric study, where
iliac-obturatory and lumbar lymphadenectomy was performed routinely in primary settings
and when not done in previous CRS in patients treated for recurrence. Colorectal resections
were routinely performed with radical technique as previously reported. Lymphadenectomy
in other districts such as the hepatic pedicle, perigastric or mesenteric stations were performed
when necessary.
In our study, overall 52,6% of patients had lymph node metastases without significant
differences between primary or recurrent forms, similarly to what reported in the literature
[45]. Although lymph node involvement worsened prognosis, related 5-year Overall survival
reached 39,6% corroborating the role of lymphadenectomy.
15. The role of HIPEC — Comparison of HIPEC vs no HIPEC
Overall, the results so far obtained by using of PRT combined with HIPEC in treating peritoneal
carcinomatosis from ovarian cancer even available mainly if not exclusively from non random‐
ized prospective studies show progressive improvement of long term survival both in primary
or recurrent forms in high volume activity centers [55].
Although general consensus about the role of maximum cytoreduction is at present undis‐
putable, criticism about HIPEC role is diffuse because of its potential high morbidity risk and
lack of prospective controlled studies.
At present both in primary and recurrent settings, a series of cases / controls studies has
demonstrated the major efficacy of the association between CRS and HIPEC compared to
traditional treatments [69-76]. Results of the first phase III prospective study recently published
[77] about this topic confirmed a significant improvement in long term survival in patients
treated with HIPEC compared with those undergoing traditional treatment with CRS and
adjuvant systemic chemotherapy.
16. Morbidity and mortality
Peritonectomy and HIPEC are integrated in a complex and aggressive procedure whose
specific related complications are difficult to distinguish, being the overall morbidity reason‐
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ably related to the whole procedure. Therefore if renal and haematological toxicity have to be
related specifically to chemotherapy activity, even for most common surgical complications
like anastomotic leak, intestinal fistulas or endoperitoneal haemorrhage, HIPEC influence
can’t be undervalued.
Overall the incidence of major complications (grade 3 and 4) ranged from 14% to 56% whose
treatment provided surgical, radiological or endoscopic re-intervention in a percentage
ranging from 13% to 19,2%.
Haematological  and  renal  toxicity  accounted  for  a  maximum  incidence  of  11  and  8  %
respectively.
Mortality rate was extremely variable ranging from 0 to 10%.
It is difficult to compare various experiences mainly because of different criteria by which
complications are defined and of different classifications with which morbidity levels are
synthetized. The number of possible complications after PRT + HIPEC is high and the likely
to have a complete scenarios of all adverse events is difficult and depends on the accuracy with
which databases are prepared and on the prospective or retrospective modalities with which
data are updated.
A detailed example of database dedicated to morbidity is described in the book edited in 2013
by Sugarbaker about the treatment of peritoneal carcinomatosis [78] with an indication of 48
adverse events arranged within 9 categories. Each adverse event is graded with a score from
I to IV, and 14 prognostic indicators have been used in uni and multivariate analyses with the
aim to identify the most significant risk factors for postoperative morbidity and mortality.
It is an interesting try to organize the adverse events but results difficult to reproduce and not
yet used in other studies. Its use can be considered particularly important for studies dedicated
to this problem. An acceptable compromise to obtain comparable data can be gained by using
of more simplified and diffused classifications of complications, such as that of Dindo’s or
CTCAE, and by performing multivariate analyses to infer the risk factors for various compli‐
cations.
Among the analyzed studies, only Bakrin’s multicentre study and the author’s monocentric
study reported the results of uni or multivariate analyses on risk factors and PCI and CC score
resulted as the most significant parameters correlated to an increased occurrence of major
complications. Cascales Campos on 91 patients treated with PRT + HIPEC for ovarian carci‐
nomatosis in various settings [76] has confirmed with multivariate analysis the role of PCI as
risk factor for major complications, associated to the performing of digestive anastomoses.
These results reliably correlate with operative mortality and re-intervention rates, as reported
in Deraco and Di Giorgio’s studies that include cases with highest mean of PCI, and with lowest
morbidity rate in patients treated as consolidation which are free of disease at second look. An
exception is represented by Pomel’s prospective study dedicated to cases treated as consoli‐
dation with Oxaliplatin based-HIPEC (CHIPOVAC); the study was stopped for excessive
morbidity. (70)
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The duration of procedure resulted as risk factor in the monocentric study, as in other reports
about using of PRT + HIPEC in both ovarian and extra-ovarian PC [72-74].
Among major complications, the anastomotic dehiscences are the most dangerous for con‐
comitant risk of severe sepsis and postoperative mortality. Risk factors for these events are
numerous and correlate with the extension of carcinomatosis, the number of intestinal
resections required for cytoreduction, the duration of procedure, the blood loss, the extensive
use of in situ destruction of parietal implants, the type of anastomosis, in particular, colorectal,
the lack of adequate bowel cleaning in occluded and sub-occluded patients, the previous
treatment with bevacizumab.
The containment of the risks lies in reducing the number of anastomoses with appropriate
evaluation of the intestinal tracts to be resected and avoiding the simultaneous performing of
multiple digestive anastomoses in conjunction with low colorectal anastomosis. In these cases
it is strategically correct to perform a colorectal resection according to Hartmann and delay
recanalization in a second intervention after the end of adjuvant treatment and after further 6
months follow up [65].
In summary, also in presence of remarkable variability of data from the analyzed studies, the
incidences of complication and mortality appear limited and comparable to those related to
major abdominal and pelvic surgery. Morbidity rate control is possible in highly active centers
with consolidated experience and specialized medical, nursing and logistic organization.
Results of trials in progress on the specific role of HIPEC shall furnish also significant data
about HIPEC related morbidity, while the use of specific protocols and prospective databases,
connected to multi-institutional experiences, can give useful data to limit morbidity in medium
period.
17. Future
The use of PRT combined with HIPEC for treating peritoneal carcinomatosis from ovarian
cancer is being widely diffused thanks to promising results in terms of survival but is not
without its critics that are primarily focused on the role of HIPEC. To date, the major criticisms
about HIPEC involve its potential influence on survival and morbidity and the lack of
prospective randomized studies as support of results of this procedure. The differing opinions
between oncological surgeons, who are more likely to use HIPEC, and oncologic gynecologists
and medical oncologists, who are more likely to use standard treatment with CRS and systemic
CHT or, more rarely, isothermic IP-CHT, plays a relevant role in such a scenario. Therefore, it
is necessary to verify whether PRT plus HIPEC can guarantee better survival compared with
standard treatments and whether the incidence of related morbidity is acceptable in compar‐
ison with other types of treatment. At present many clinical trials are ongoing about the efficacy
of PRT and HIPEC, most of them are focused specifically on HIPEC role, both in primary and
in recurrent patients (Tab 8).
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Studies Time Drug Type of study Identificationnumber*
Safety and Pharmacokinetics of Intraoperative
Hyperthermic Intraperitoneal Chemoperfusion
(HIPEC) With Cisplatin to Treat Platinum-
sensitive Recurrent Ovarian Cancer
Recurrence Cisplatin Non-Randomized NCT01387399
Hyperthermic Intra-peritoneal Chemotherapy
(HIPEC) in Ovarian Cancer Recurrence
(HORSE)
Recurrence Cisplatin Randomized NCT01539785
Intraoperative Hyperthermic Intraperitoneal
Chemotherapy With Ovarian Cancer
Primary
Recurrence Cisplatin Randomized NCT01091636
Phase 3 Trial Evaluating Hyperthermic
Intraperitoneal Chemotherapy in Upfront
Treatment of Stage IIIC Epithelial Ovarian
Cancer (Chorine)
Primary CDDP+Paclitaxel Randomized NCT01628380
Secondary Debulking Surgery +/- Hyperthermic
Intraperitoneal Chemotherapy in Stage III
Ovarian Cancer
Recurrence - Randomized NCT00426257
Hyperthermic Intra-Peritoneal Chemotherapy
(HIPEC) in Relapse Ovarian Cancer Treatment
(CHIPOR)
Recurrence Cisplatin Randomized NCT01376752
Feasibility Study of HIPEC for Patients With
Stage III or Only Pleural Stage IV Ovarian
Carcinoma in First Line Therapy
Primary Cisplatin Safety/Efficacy NCT01709487
WCC# 59 Hyperthermic Intraperitoneal
Chemotherapy Utilizing Carboplatin in First
Recurrence Ovarian Cancer
Recurrence Carboplatin Safety/Efficacy NCT01144442
Outcomes After Secondary Cytoreductive
Surgery With or Without Carboplatin
Hyperthermic Intraperitoneal Chemotherapy
(HIPEC) Followed by Systemic Combination
Chemotherapy for Recurrent Platinum-Sensitive
Ovarian, Fallopian Tube, or Primary Peritoneal
Cancer
Recurrence Carboplatin Randomized NCT01767675
A Phase II Combined Modality Protocol of
Debulking Surgery With HIPEC Followed by
Intraperitoneal Chemotherapy for the Treatment
of Recurrent Ovarian, Primary Peritoneal &
Fallopian Tube Cancers
Recurrence Cisplatin Safety/Efficacy NCT01659554
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Studies Time Drug Type of study Identificationnumber*
Quality of Life and Survivorship Care in
Patients Undergoing Hyperthermic
Intraperitoneal Chemotherapy (HIPEC)
Primary
Recurrence - Efficacy NCT01126346
Surgery and Chemotherapy With or Without
Chemotherapy After Surgery in Treating
Patients With Ovarian, Fallopian Tube,
Uterine, or Peritoneal Cancer
Primary
Recurrence Cisplatin Safety NCT01970722
Table 8. Ongoing clinical trials on HIPEC in EOC. [79-90]
Results of such trials may help to confirm the role of HIPEC in various subsets of patients
treated in primary setting and contribute to specify also the prognostic role of NACT and
chemoresistance.
An half of ongoing studies are referred to recurrent patients. In the most of such trials, only
platinum sensitive recurrences are considered. All of these studies are aimed to evaluate the
prognostic role of HIPEC in terms of OS, PFS and DFS, having a variety of secondary outcomes
such as the role of different combinations of chemotherapy drugs, the use of IP CHT after
HIPEC, the QoL, toxicity and morbidity.
18. Conclusions
At present, lacking results of prospective randomized phase III studies, the role of PRT and
HIPEC in treating peritoneal carcinomatosis from EOC can be reliably evaluated by the studies
reported in this research which include over 1900 treated cases. The overall size of these case
studies is a solid base to reliably identify the trend of results regardless of the study limitations
discussed above.
On the basis of analysed results, following conclusions can be drawn:
• PRT plus HIPEC guarantee significant percentage of long-term overall and progression free
survival in primary and recurrent settings.
• In all settings, complete cytoreduction represents the most significant prognostic factor.
• High PCI levels do not constitute a limitation for this procedure if optimal CRS is technically
feasible.
• The prognostic role of NACT and Platinum-based chemoresistance is uncertain; but NACT
and platinum chemoresistance should be better assessed, the first for when to be applied
and the other for its application even in post-HIPEC setting
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• Major complications and mortality rates are similar to those related to major abdominal
pelvic surgery and are not different after primary or secondary cytoreduction. PCI and CC
scores represent the most significant risk factors for major complications.
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